Geode Capital Management LLC bought a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 363,269 shares of the company's stock, valued at approximately $5,973,000. Geode Capital Management LLC owned about 0.68% of Upstream Bio at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Alliancebernstein L.P. bought a new position in Upstream Bio in the 4th quarter worth $18,270,000. Wellington Management Group LLP bought a new position in Upstream Bio in the fourth quarter worth about $25,632,000. Norges Bank purchased a new stake in Upstream Bio in the fourth quarter worth about $16,440,000. JPMorgan Chase & Co. bought a new stake in Upstream Bio during the 4th quarter valued at approximately $786,000. Finally, Corebridge Financial Inc. purchased a new position in shares of Upstream Bio during the 4th quarter worth approximately $142,000.
Upstream Bio Stock Down 1.0 %
Shares of NASDAQ:UPB traded down $0.09 during trading on Thursday, hitting $9.17. The stock had a trading volume of 73,604 shares, compared to its average volume of 321,715. Upstream Bio, Inc. has a 12 month low of $5.14 and a 12 month high of $29.46. The firm's fifty day moving average is $7.92 and its 200 day moving average is $14.33.
About Upstream Bio
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Stories
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
